Health Care [ 4/12 ] | Biotechnology [ 18/72 ]
NASDAQ | Common Stock
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies.
It develops TCR Library, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers; hunTR, a human neoantigen T-cell receptor engine.
The company has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; and a patent license agreement, and research and development agreement with the National Cancer Institute.
The company was formerly known as ZIOPHARM Oncology, Inc. and changed its name to Alaunos Therapeutics, Inc. in January 2022.
Alaunos Therapeutics, Inc. was founded in 2003 and is headquartered in Houston, Texas.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Apr 1, 24 | -0.49 Decreased by -1.13 K% | -0.45 Decreased by -8.89% |
| Mar 5, 24 | -0.49 Decreased by -1.13 K% | -0.45 Decreased by -8.89% |
| Nov 14, 23 | -0.04 Increased by 0.00% | -0.04 |
| Aug 14, 23 | -0.04 Increased by +20.00% | -0.04 |
| May 10, 23 | -0.04 Increased by +20.00% | -0.04 |
| Mar 7, 23 | -0.04 Increased by +20.00% | -0.07 Increased by +42.86% |
| Nov 14, 22 | -0.04 Increased by +63.64% | -0.08 Increased by +50.00% |
| Aug 15, 22 | -0.05 Increased by +54.55% | -0.07 Increased by +28.57% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 0.00 Decreased by -100.00% | -8.48 M Increased by +10.19% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 4.00 K Increased by +N/A% | -8.77 M Increased by +10.47% | Decreased by -219.32 K% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -9.35 M Increased by +10.86% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 11.00 K Increased by +N/A% | -9.80 M Increased by +16.91% | Decreased by -89.06 K% Decreased by N/A% |
| Sep 30, 22 | 2.91 M Increased by +631.41% | -9.44 M Increased by +58.48% | Decreased by -324.22% Increased by +94.32% |
| Jun 30, 22 | 0.00 Decreased by N/A% | -9.80 M Increased by +56.78% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 22 | 0.00 Decreased by N/A% | -10.49 M Increased by +51.33% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 21 | 0.00 Decreased by N/A% | -11.79 M Increased by +48.22% | Decreased by N/A% Decreased by N/A% |